Brendon M. Stiles, MD

Articles

Surgical Perspectives: Who Are the Best Candidates for Neoadjuvant Chemoimmunotherapy?

July 8th 2025

Panelists discuss how surgeons evaluate candidates for neoadjuvant chemoimmunotherapy by emphasizing that all patients with stage II and III disease should be considered regardless of PD-L1 or mutation status, while highlighting the importance of multidisciplinary collaboration in treatment decisions.

CheckMate 77T: Updated Survival and Biomarker Insights Shaping Early-Stage NSCLC Care

July 8th 2025

Panelists discuss how the CheckMate 77T perioperative trial updates showed that even patients receiving fewer than 4 cycles of neoadjuvant therapy still benefited, and circulating tumor DNA (ctDNA) clearance serves as an independent biomarker for predicting outcomes regardless of pathologic response status.

CheckMate 816 at ASCO 2025: OS Update and Impact on Early-Stage NSCLC Care

June 27th 2025

Panelists discuss how the CheckMate 816 overall survival data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated a significant survival benefit with neoadjuvant chemoimmunotherapy, particularly in patients with higher PD-L1 expression and those achieving pathologic complete responses (pCRs).

Resectable Early-Stage NSCLC: How the Standard of Care Is Evolving

June 27th 2025

Panelists discuss how the standard of care for resectable early-stage non–small cell lung cancer (NSCLC) has evolved from adjuvant chemotherapy alone to neoadjuvant chemoimmunotherapy and perioperative approaches that combine preoperative treatment with continued immunotherapy after surgery.

FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC

October 3rd 2024

Drs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.

Dr Stiles on the FDA Approval of Perioperative Durvalumab Plus Chemo in NSCLC

August 15th 2024

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early

December 1st 2022

Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.

Dr. Stiles on Treatment Advances Made in Early-Stage Lung Cancer

January 18th 2021

Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.

Multidisciplinary Management of Patients With Stage III NSCLC

July 13th 2020

Integrating Perioperative Immunotherapy Strategies in NSCLC

July 13th 2020

Molecular testing in Patients With Metastatic NSCLC

July 13th 2020

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

July 13th 2020

Varied Timing of IO Therapy in Patients With Stage III NSCLC

July 13th 2020

Treating for Stage III NSCLC After Progression on Durvalumab

July 13th 2020

Durvalumab in Stage III NSCLC Based on Performance Status

July 13th 2020

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

July 13th 2020

Mediastinal Staging in Non–Small Cell Lung Cancer

July 13th 2020

Dr. Stiles on Surgical Considerations in Lung Cancer

November 12th 2019

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.

There's an App for That: Keeping Patients and Physicians on Track

September 1st 2016

In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.